1206968-77-5

Usage

Uses

Used in Pharmaceutical Synthesis:
2-(5-bromopyridin-2-yl)ethanol is utilized as a building block for the creation of pharmaceuticals, leveraging its reactivity to form new compounds with potential therapeutic applications.
Used in Organic Compounds Synthesis:
It serves as a key component in the synthesis of a variety of organic compounds, contributing to the development of new chemical entities with diverse properties and uses.
Used as a Reagent in Chemical Reactions:
2-(5-bromopyridin-2-yl)ethanol is employed as a reagent in various chemical reactions, facilitating the formation of desired products through its nucleophilic properties.
Used in Manufacturing Processes:
It functions as an intermediate in the manufacturing of different products, playing a crucial role in the production process to achieve the final desired outcome.
Used in Research and Development:
2-(5-bromopyridin-2-yl)ethanol is applied in research and development settings, particularly within the pharmaceutical and chemical industries, to explore new avenues for chemical synthesis and compound development.
Used in the Chemical Industry:
Within the chemical industry, 2-(5-bromopyridin-2-yl)ethanol is used as a versatile nucleophilic reagent, contributing to the advancement of organic chemistry and the creation of novel chemical processes and products.

InChI:InChI=1S/C7H8BrNO/c8-6-1-2-7(3-4-10)9-5-6/h1-2,5,10H,3-4H2

Upstream product

• 624-28-2 2,5-dibromopyridine 
• 24850-33-7 allyltributylstanane 
• 192642-85-6 2-(5-bromopyridin-2-yl)acetic acid 
• 2402-97-3 3-bromopyridine N-oxide 
• 626-55-1 3-Bromopyridine 
• 192642-83-4 5-(5-bromo-1H-2-pyridinylidene)-2,2-dimethyl-[1,3]dioxane-4',6-dione 
• 3430-13-5 5-bromo-2-methylpyridine 
• 68-12-2 N,N-dimethyl-formamide 
• 67-56-1 methanol 

Downstream Products

• 1582261-92-4 2,2-dichloro-N-((1R,2S)-3-fluoro-1-hydroxy-1-(4-(6-(2-(methylsulfonyl)ethyl)pyridin-3-yl)phenyl)propan-2-yl)acetamide 

Relevant academic research and scientific papers

FUNCTIONALIZED HETEROCYCLIC COMPOUNDS AS MODULATORS OF STIMULATOR OF INTERFERON GENES (STING)

The present invention relates to compound-linker constructs and antibody-drug-conjugates of compounds of formula (I) that are useful as modulators of STING (Stimulator of Interferon Genes).

INDANE DERIVATIVES FOR USE IN THE TREATMENT OF BACTERIAL INFECTION

The invention relates to a compound which is an indane according to Formula (I), or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, L, M, ?, n, p, and q are as defined herein. The compounds are useful in the treatment of antibacterial infection either as stand alone antibiotics, or in combination with further antibiotics.

APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS AND USES THEREOF

Described herein are ASK1 inhibitors and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of blood disease, autoimmune disorders, pulmonary disorders, hypertension, inflammatory diseases, fibrotic diseases, diabetes, diabetic nephropathy, renal diseases, respiratory diseases, cardiovascular diseases, acute lung injuries, acute or chronic liver diseases, and neurodegenerative diseases.

Identification of a novel orally bioavailable phosphodiesterase 10A (PDE10A) inhibitor with efficacy in animal models of schizophrenia.

We report the continuation of a focused medicinal chemistry program aimed to further optimize a series of imidazo[1,2-a]pyrazines as a novel class of potent and selective phosphodiesterase 10A (PDE10A) inhibitors. In vitro and in vivo pharmacokinetic and pharmacodynamic evaluation allowed the selection of compound 25a for its assessment in preclinical models of psychosis. The evolution of our medicinal chemistry program, structure-activity relationship (SAR) analysis, as well as a detailed pharmacological profile for optimized lead 25a are described.

PHENICOL ANTIBACTERIAL AGENTS

The present invention provides novel phenicol derivatives, their use for the treatment of infections in mammals, pharmaceutical composition containing these novel compounds, and methods for the preparation of these compounds.

IMIDAZO[1,2-a]PYRAZINE DERIVATIVES AND THEIR USE FOR THE PREVENTION OR TREATMENT OF NEUROLOGICAL, PSYCHIATRIC AND METABOLIC DISORDERS AND DISEASES

The present invention relates to novel imidazo[1,2-a]pyrazine derivatives which are inhibitors of the phosphodiesterase 10 enzyme (PDE10) and which are useful for the treatment or prevention of neurological, psychiatric and metabolic disorders in which the PDE10 enzyme is involved. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and compositions, to the use of such compounds or pharmaceutical compositions for the prevention or treatment of neurological, psychiatric and metabolic disorders and diseases.

IMIDAZO [1, 2 -A] PYRAZINE DERIVATIVES AND THEIR USE FOR THE PREVENTION OR TREATMENT OF NEUROLOGICAL, PSYCHIATRIC AND METABOLIC DISORDERS AND DISEASES

The present invention relates to novel imidazo[1,2-a]pyrazine derivatives which are inhibitors of the phosphodiesterase 10 enzyme (PDE10) and which are useful for the treatment or prevention of neurological, psychiatric and metabolic disorders in which the PDE10 enzyme is involved. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and compositions, to the use of such compounds or pharmaceutical compositions for the prevention or treatment of neurological, psychiatric and metabolic disorders and diseases.

C-LINKED HYDROXAMIC ACID DERIVATIVES USEFUL AS ANTIBACTERIAL AGENTS

The present invention is directed to a new class of hydroxamic acid derivatives, their use as LpxC inhibitors, and more specifically their use to treat bacterial infections.

GPR119 AGONIST

A cyclic amine derivative represented by the formula (II) is a GPR119 agonist, and is used as an agent for treating diabetes. wherein Ar0 is phenyl or phenyl having a substituent such as C1-8 alkylsulfonyl or the like, pyridyl, or pyridyl having a substituent such as C1-8 alkylsulfonyl; A0 is (CH2)p, O, or the like; B0 is (CH2)q, or the like, provided that B0 is neither O nor NR25 when A0 is O or NR24; one of U0 and V0 is N, and the other is N or CR26; each of X0\ and Y0 is C1-3 alkylene or C1-3 alkylene having a substituent; R23 is a C1-8 alkyl group or the like; each of R21 and R22 is hydrogen, a halogen atom, or the like.

OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION

This invention relates to potent potassium channel blocker compounds of Formula (I) or a formulation thereof for the treatment of glaucoma and other conditions which leads to elevated intraoccular pressure in the eye of a patient. This invention also rela